Iovance Biotherapeutics To Present Clinical And Pre-Clinical Data For Tumor Infiltrating Lymphocyte Therapies At Society For Tumor Immunotherapy Of Cancer's 38th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has announced the publication of abstracts for poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting. The data includes a four-year analysis of pooled Cohorts 2 and 4 of the C-144-01 trial, which reports the longest follow-up data on lifileucel treatment outcomes in patients with anti–PD-1–refractory advanced melanoma treated with TIL therapy.

October 31, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics is set to present significant clinical data for its TIL therapies at the upcoming SITC meeting. This includes a four-year analysis of lifileucel treatment outcomes, which could potentially boost investor confidence in the company's innovative cancer treatments.
The presentation of positive long-term clinical data is typically seen as a positive event for biotech companies, as it can increase investor confidence in the company's products and potentially lead to increased demand for the company's stock. In this case, the four-year analysis of lifileucel treatment outcomes could be particularly impactful, as it demonstrates the potential efficacy of the treatment in a large population of patients with advanced melanoma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100